Guidance. Clarity. Direction.

Carter, DeLuca & Farrell LLP, a leader in intellectual property law, provides cost-effective services to clients from around the world, protecting innovations in a wide range of technologies.

Throughout the phases of product or brand development, we form a critical part of our clients’ development teams to provide preparation, prosecution and clearance services to maximize protection while navigating through freedom-to-operate challenges. We also provide extensive IP due diligence services and IP asset assimilation to help our clients achieve their business objectives.

Search Attorneys

Events

Aug
5 – 6
2019
Design Rights Boot Camp AttendingJoin Carter, DeLuca & Farrell LLP Partner Pina Campagna and the American Intellectual Property Law Association (AIPLA) for the Design Rights Boot Camp on...

CAFC Update

PAPST LICENSING GMBH & CO. KG v. SAMSUNG ELECTRONICS AMERICA May 23, 2019

Samsung successfully petitioned the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office to institute an inter partes review (IPR) of all claims of Papst Licensing’s U.S. Patent No. 9,189,437 relating to an interface device that achieves high data transfer rates between a data device and a host computer without the need for a...

Samsung successfully petitioned the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office to institute an inter partes review (IPR)...

QUEST INTEGRITY USA, LLC v. COKEBUSTERS USA INC. May 21, 2019

Quest appeals a judgment of the District Court in favor of Cokebusters holding on summary judgment that claims of U.S. Patent No. 7,542,874 (a system and method for displaying inspection data collected from certain commercial furnaces ) were invalid under 35 U.S.C. § 102(b) because the claimed invention was offered for sale more than one year prior...

Quest appeals a judgment of the District Court in favor of Cokebusters holding on summary judgment that claims of U.S. Patent No. 7,542,874...

NUVO PHARMACEUTICALS v. DR. REDDY’S LABORATORIES INC. May 15, 2019

Nuvo sued three Generics manufacturers (Dr. Reddy’s Laboratories, Mylan Pharmaceuticals, and Lupin Pharmaceuticals) to prevent their ANDA products from going to market, if approved, before the expiration of U.S. Patent Nos. 6,926,907 and 8,557,285, relating to the coordinated the release of an acid inhibitor (such as proton pump inhibitors (“PPIs”) like omeprazole and esomeprazole) and an NSAID...

Nuvo sued three Generics manufacturers (Dr. Reddy’s Laboratories, Mylan Pharmaceuticals, and Lupin Pharmaceuticals) to prevent their ANDA products from going to market, if...